<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077166</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1123-CA</org_study_id>
    <nct_id>NCT02077166</nct_id>
  </id_info>
  <brief_title>Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in&#xD;
      combination with lenalidomide and rituximab in subjects with relapsed/refractory Diffuse&#xD;
      Large B-Cell Lymphoma (DLBCL) not eligible for transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1b: In the dose escalation portion of the study, various cohorts with escalating doses&#xD;
      of lenalidomide may be explored, using the 3+3+3 principle for dose determination.&#xD;
&#xD;
      Phase 2: This will be conducted as an international, multicenter, open-label study. Eligible&#xD;
      subjects will receive ibrutinib, lenalidomide and rituximab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">December 17, 2020</completion_date>
  <primary_completion_date type="Actual">December 17, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Determine the maximally tolerated dose (MTD) and /or the recommended Phase 2 (RP2) dose of lenalidomide in combination with fixed doses of ibrutinib and rituximab in subjects with relapsed or refractory DLBCL.</measure>
    <time_frame>Up to 45 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall response rate (ORR)</measure>
    <time_frame>Up to 45 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall response rate(ORR)</measure>
    <time_frame>Up to 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Duration of response (DOR)</measure>
    <time_frame>Up to 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Progression free survival (PFS)</measure>
    <time_frame>Up to 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Overall survival (OS)</measure>
    <time_frame>Up to 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Complete response (CR)</measure>
    <time_frame>Up to 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Safety and tolerability of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed or refractory non-GCB DLBCL.</measure>
    <time_frame>Up to 45 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Relapsed Diffuse Large B-Cell Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase 1: Dose Level -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Dose Level 1+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2Phase 1: Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <arm_group_label>2Phase 1: Dose Level 3</arm_group_label>
    <arm_group_label>Phase 1: Dose Level -1</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 1</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 1+</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 2</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <arm_group_label>2Phase 1: Dose Level 3</arm_group_label>
    <arm_group_label>Phase 1: Dose Level -1</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 1</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 1+</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 2</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>2Phase 1: Dose Level 3</arm_group_label>
    <arm_group_label>Phase 1: Dose Level -1</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 1</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 1+</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 2</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed relapsed/ refractory DLBCL&#xD;
&#xD;
          -  Must have previously received first line treatment regimen&#xD;
&#xD;
          -  Must be ineligible for high dose therapy/ stem cell transplantation&#xD;
&#xD;
          -  Measurable disease sites on CT scan (&gt;1.5 cm in longest dimension)&#xD;
&#xD;
          -  PT/INR &lt;1.5 x ULN and PTT (aPTT) &lt;1.5 x ULN&#xD;
&#xD;
          -  Men and women â‰¥18 years of age&#xD;
&#xD;
          -  ECOG &lt; 2&#xD;
&#xD;
          -  Adequate hepatic and renal function&#xD;
&#xD;
          -  Adequate hematologic function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medically apparent central nervous system lymphoma or leptomeningeal disease&#xD;
&#xD;
          -  History of allogeneic stem-cell (or other organ) transplantation&#xD;
&#xD;
          -  Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 2&#xD;
             weeks&#xD;
&#xD;
          -  Radio- or toxin-immunoconjugates within 10 weeks&#xD;
&#xD;
          -  Concurrent enrollment in another therapeutic investigational study or have previously&#xD;
             taken ibrutinib and/or lenalidomide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jutta K. Neuenburg, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics LLC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Health Barrett Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Ohio Oncology/ Hematology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of TN Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Charles Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates, PS</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialities, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen - Campus Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Campus Grosshadern</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar - Technische Universitaet Muenchen, III. Medizinische Klinik und Polyklinik</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg, Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Leeds Teaching Hospitals</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

